scholarly journals Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study

2021 ◽  
pp. 106625
Author(s):  
Alejandra Castanon ◽  
Leonardo I. Green ◽  
Peter Sasieni
2019 ◽  
Vol 147 (3) ◽  
pp. 887-896
Author(s):  
Rebecca Landy ◽  
Peter D. Sasieni ◽  
Christopher Mathews ◽  
Charles L. Wiggins ◽  
Michael Robertson ◽  
...  

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0253801
Author(s):  
Luana F. Tanaka ◽  
Dirk Schriefer ◽  
Kathrin Radde ◽  
Gunther Schauberger ◽  
Stefanie J. Klug

Background We investigated the uptake of opportunistic cervical cancer screening (CCS) and other risk factors and their association with cervical cancer in Germany in a case-control study. Methods and findings We recruited incident cases of cervical cancer (ICD-10 C53) diagnosed between 2012 and 2016 and matched with three population-based controls, based on age and region of residence. Cases and controls reported their CCS participation during the past ten years (frequent: every three years; no or infrequent: less than every three years) and other relevant variables. We fitted conditional logistic regression models, reporting odds ratios (OR) and 95% confidence intervals (95% CI). We report overall and stratified analyses by histologic group (squamous cell–SCC, and adenocarcinoma–AC), T category (T1 and T2+), and age (<50 and ≥50 years). We analysed 217 cases and 652 matched controls. 53.0% of cases and 85.7% of controls attended CCS frequently. In the overall adjusted model, no or infrequent participation in CCS (OR 5.63; 95% CI 3.51 to 9.04), having had more than one sexual partner (OR 2.86; 95%CI 1.50 to 5.45) and obesity (OR 1.69; 95% CI 1.01 to 2.83) were associated with cervical cancer. Twelve years of schooling (OR 0.37; 95% CI 0.23 to 0.60) and a net monthly income of €3000 or more (OR 0.50; 95% CI 0.30 to 0.82) were protective factors. In the stratified analyses, no or infrequent participation was associated with T1 (OR 4.37; 95% CI 2.48 to 7.71), T2+ (OR 10.67; 95% CI 3.83 to 29.74), SCC (OR 6.88; 95% CI 4.08 to 11.59) and AC (OR 3.95; 95% CI 1.47 to 10.63). Conclusion Although women who frequently attended CCS were less likely to develop cervical cancer, especially larger tumours, the high proportion of cases who had been frequently screened prior to diagnosis underscores the need to investigate the quality of cytology and treatment of precancerous lesions in Germany.


2014 ◽  
Vol 179 (9) ◽  
pp. 1107-1114 ◽  
Author(s):  
A. S. Rustagi ◽  
A. Kamineni ◽  
S. Weinmann ◽  
S. D. Reed ◽  
P. Newcomb ◽  
...  

2014 ◽  
Vol 133 (2) ◽  
pp. 167-171 ◽  
Author(s):  
Danielle Vicus ◽  
Rinku Sutradhar ◽  
Yan Lu ◽  
Laurie Elit ◽  
Rachel Kupets ◽  
...  

2006 ◽  
Vol 16 (3) ◽  
pp. 1278-1282
Author(s):  
N. C. Nogueira De Souza ◽  
S. M.F. Brenna ◽  
F. Campos ◽  
K. J. Syrjänen ◽  
E. C. Baracat ◽  
...  

Recent data implicate that cytokine gene polymorphisms are important in pathogenesis of various neoplastic and nonneoplastic human diseases, and it was recently suggested that polymorphisms in interleukin (IL)-6 might increase the risk of gynecological malignancies, including cervical carcinomas. The aim of this case–control study is to compare the IL-6 polymorphisms in cervical cancer patients and healthy controls and to assess whether any of these polymorphisms would increase the risk of developing cervical cancer. The material in this case–control study consists of 56 patients with cervical carcinoma and 253 population-based control subjects, all ethnic Brazilian women. Control subjects were cancer-free women, following a negative cervical cytology and colposcopy. IL-6 genotyping was performed using a polymerase chain reaction–based restriction fragment length polymorphism. Distribution of the GG, GC, and CC genotypes in cases and controls was significantly different (P = 0.033). Compared with the GG genotype as reference, the adjusted odds ratio for the combined GC and CC genotypes in cancer patients was 1.90 (95% confidence interval, 1.1–3.4). These data suggest that women carrying at least one C genotype in their IL-6 promoter region (−174G→C) are at higher risk of developing cervical cancer.


2019 ◽  
Vol 30 (1) ◽  
pp. 29-34
Author(s):  
Laurence Bernard ◽  
Danielle Fearon ◽  
Susan McFaul ◽  
Wylam Faught

IntroductionThe elimination of cervical cancer will only be achievable through primary and secondary prevention. The aim of this study was to determine the effect of primary care enrolment on the prevention of advanced cervical cancer.MethodsUsing a population-based case–control study, all women (n=5548) above 18 years of age who were diagnosed with cervical cancer between January 2006 and December 2015 in Ontario, Canada were selected for the analysis. The controls were women (n=27 740) above 18 years of age and without a diagnosis of cervical cancer. Five controls were matched to each case by year of birth. Descriptive statistics were used to compare the patients and controls. Multiple imputations and logistic regression were used to estimate the correlation between enrolment with a primary care provider and diagnosis of cervical cancer.ResultsA total of 44% of advanced cervical cancer patients and 56% of controls had a screening test 10 years before the index date. The odds of having had a Pap test in the 3 and 10 years before were higher when patients were enrolled with a primary care provider (OR 3.5 and 5.1, p<0.001). The correlation between screening and advanced cervical cancer (stage II–IV) incidence was modified by primary care enrolment: if the patient was enrolled with a primary care provider and had at least one screen in the previous 10 years, the OR of developing advanced cervical cancer was 0.42 (95% CI 0.40 to 0.43); if the patient was not enrolled the OR was 0.78 (95% CI 0.72 to 0.84).DiscussionPrimary care enrolment is an effect modifier of cervical cancer screening on advanced cervical cancer incidence. Efforts should be made to increase the capacity of primary care providers to offer screening in order to eradicate cervical cancer.


Sign in / Sign up

Export Citation Format

Share Document